StockNews.AI
PCRX
StockNews.AI
120 days

DOMA Perpetual Supports Pacira's New $300 Million Share Repurchase Authorization as a Meaningful Step to Enhance Value for Shareholders

1. DOMA Perpetual owns 4.2% of Pacira, believes stock is undervalued. 2. Announced $300 million buyback program signifies commitment to shareholder value. 3. $300 million repurchase and focus on margins expected to boost returns. 4. Management must execute initiatives to capture growth momentum. 5. Positive outlook for long-term value creation and earnings scaling.

Shares Buyback
+3.41%Current Return
VS
+0.07%S&P 500
$24.6504/21 08:31 AM EDTEvent Start
$25.4904/22 03:00 PM EDTLatest Updated
7m saved
Insight
Article

FAQ

Why Bullish?

The announcement of a large buyback program often positively influences stock prices. For instance, similar past buybacks have led to stock price appreciation due to reduced share count and perceived management confidence.

How important is it?

The strategic buyback and focus on margins indicate significant future cash flow improvements, enhancing investor sentiment and stock price potential.

Why Long Term?

The initiatives announced by DOMA Perpetual, particularly the buyback, are designed to create lasting shareholder value, aligning with Pacira's growth strategy over time.

Related Companies

SPYAMGNPFE
(PRNewsfoto/DOMA Perpetual) DOMA Perpetual Believes Pacira's Stock Is Undervalued, Presenting an Opportunity to Execute the Largest Buyback in the Company's History, /PRNewswire/ -- DOMA Perpetual Capital Management LLC (collectively with its affiliates, "DOMA Perpetual" or "We") is a fundamentals-based, value-oriented asset management firm which beneficially owns approximately 4.2% of the outstanding shares of common stock of Pacira BioSciences, Inc. (NASDAQ: PCRX) ("Pacira" or the "Company").Following constructive engagement with Pacira, DOMA Perpetual believes the Company's new capital allocation announcementi represents the Board's firm commitment to enhancing shareholder value. In DOMA Perpetual's view, the announced initiatives reflect Pacira's robust financial position and the Board's commitment to disciplined capital allocation. The combination of the $300 million dollar share repurchase program and a new emphasis on increasing margins at the pre-tax net income level is anticipated to strengthen shareholder returnii. The onus now falls on management to effectively execute these important initiatives. "After engaging in conversations with representatives of the Company's Board and management team, we are encouraged by the clear steps Pacira is taking to drive long-term value creation," said Pedro Escudero, CEO and CIO of DOMA Perpetual.  "We believe Pacira has entered a period of rapid growth; the new capital allocation priorities reflect the Company's considerable momentum as it continues scaling earnings and free cash flow, enabling it to return meaningful capital to shareholders while still investing in growth. It is our conviction the stock is undervalued relative to its historical average valuation and, more importantly, relative to the multiyear cycle of growth ahead."Contact:DOMA Perpetual Capital Management LLC[email protected] DisclaimerThis press release has been prepared by DOMA Perpetual Management LLC and its affiliates ("DOMA Perpetual").  The views expressed herein reflect the opinions of DOMA Perpetual and are based on publicly available information with respect to Pacira BioSciences, Inc. ("Pacira" or the "Company"). DOMA Perpetual recognizes that there may be confidential information in the possession of the Company that could lead it or others to disagree with DOMA Perpetual's conclusions. DOMA Perpetual reserves the right to change or modify any of such views or opinions at any time and for any reason and expressly disclaims any obligation to correct, update, or revise the information contained herein or to otherwise provide any additional materials.                For the avoidance of doubt, this press release was not produced by any person that is affiliated with Pacira, nor was its content endorsed by Pacira. This press release is provided merely as information and is not intended to be, nor should it be construed as, an offer to sell or a solicitation of an offer to buy any security nor as a recommendation to purchase or sell any security. One or more funds managed by DOMA Perpetual currently beneficially owns shares of the Company.Some of the materials in this press release contain forward-looking statements. All statements contained herein that are not clearly historical in nature or that necessarily depend on future events are forward-looking, and the words "anticipate," "believe," "expect," "potential," "could," "opportunity," "estimate," "plan," "once again," "achieve," and similar expressions are generally intended to identify forward-looking statements. The projected results and statements contained herein that are not historical facts are based on DOMA Perpetual's current expectations, speak only as of the date of these materials and involve risks, uncertainties and other factors that may cause actual results, performances or achievements to be materially different from any future results, performances or achievements expressed or implied by such projected results and statements. Assumptions relating to the foregoing involve judgments with respect to, among other things, future economic competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the control of DOMA Perpetual._______________________________i Pacira BioSciences, Inc. https://www.globenewswire.com/news-release/2025/04/17/3063878/0/en/Pacira-BioSciences-Reaffirms-Commitment-to-Enhancing-Value-for-All-Shareholders.html ii Pacira BioSciences, Inc. https://www.globenewswire.com/news-release/2025/04/17/3063878/0/en/Pacira-BioSciences-Reaffirms-Commitment-to-Enhancing-Value-for-All-Shareholders.htmlSOURCE DOMA Perpetual WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In

Related News